posted fourth-quarter earnings slightly above expectations, helped in part by strong overseas sales and the declining dollar.
The medical-device maker earned $137 million, or 16 cents a share, in the three months ended Dec. 31, compared with $105 million, or 12 cents a share, a year ago. The results included special charges totaling $4 million. Excluding the charges, the company earned $141 million, or 17 cents a share, compared with $130 million, or 15 cents a share, in the year-earlier period.
Analysts were expecting 16 cents a share. Today's results matched preliminary results reported Jan. 13.
Total sales were $939 million, up 15% from the previous year's $814 million. Boston Scientific said that excluding the favorable impact of $57 million of foreign currency fluctuations, net sales were $882 million.
"We further strengthened our market leadership position in drug-eluting stents in Europe and other international markets during the fourth quarter," said the company in a statement, adding that it will launch its paclitaxel-eluting stent system in the United States later in the current quarter.
Shares of Natick, Mass.-based Boston Scientific were lately up 46 cents, or 1.1%, at $41.25.